Revenues (Tables)
|
3 Months Ended |
Mar. 29, 2024 |
| Revenue from Contract with Customer [Abstract] |
|
| Schedule of Disaggregation of Revenue |
Revenues consisted of the following (in thousands): | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, | | | | | | 2024 | | 2023 | | | | Product revenues: | | | | | | | | | | | Gross product revenues | | | | | $ | 563,785 | | | $ | 521,322 | | | | | Discounts and allowances | | | | | (185,262) | | | (157,922) | | | | | Net product revenues | | | | | 378,523 | | | 363,400 | | | | | Collaboration revenues: | | | | | | | | | | | License revenues | | | | | 44,676 | | | 38,292 | | | | | Collaboration services revenues | | | | | 2,027 | | | 7,096 | | | | | Total collaboration revenues | | | | | 46,703 | | | 45,388 | | | | | Total revenues | | | | | $ | 425,226 | | | $ | 408,788 | | | |
Net product revenues by product were as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, | | | | | | 2024 | | 2023 | | | | CABOMETYX | | | | | $ | 376,417 | | | $ | 361,773 | | | | | COMETRIQ | | | | | 2,106 | | | 1,627 | | | | | Net product revenues | | | | | $ | 378,523 | | | $ | 363,400 | | | |
|
| Schedule of Concentration Risks |
The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows: | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, | | | | | | 2024 | | 2023 | | | | Affiliates of AmerisourceBergen Corporation | | | | | 19 | % | | 17 | % | | | | Affiliates of McKesson Corporation | | | | | 18 | % | | 17 | % | | | | Affiliates of CVS Health Corporation | | | | | 17 | % | | 17 | % | | | | Accredo Health, Incorporated | | | | | 12 | % | | 12 | % | | | | Affiliates of Optum Specialty Pharmacy | | | | | 10 | % | | 10 | % | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: | | | | | | | | | | | | | | | | | March 31, 2024 | | December 31, 2023 | | | | | | Affiliates of McKesson Corporation | 26 | % | | 21 | % | | | | | | Affiliates of AmerisourceBergen Corporation | 20 | % | | 17 | % | | | | | | Ipsen Pharma SAS | 19 | % | | 19 | % | | | | | | Affiliates of CVS Health Corporation | 15 | % | | 20 | % | | | | | | Cardinal Health, Inc. | 10 | % | | 11 | % | | | | |
|
| Schedule of Revenues Disaggregated by Geographic Region |
Total revenues by geographic region were as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, | | | | | | 2024 | | 2023 | | | | U.S. | | | | | $ | 381,937 | | | $ | 367,441 | | | | | Europe | | | | | 35,703 | | | 33,534 | | | | | Japan | | | | | 7,586 | | | 7,813 | | | | | Total revenues | | | | | $ | 425,226 | | | $ | 408,788 | | | |
|
| Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances |
The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | Chargebacks, Discounts for Prompt Payment and Other | | Other Customer Credits/Fees and Co-pay Assistance | | Rebates | | | | Total | Balance at December 31, 2023 | $ | 25,221 | | | $ | 19,721 | | | $ | 39,898 | | | | | $ | 84,840 | | | Provision related to sales made in: | | | | | | | | | | | Current period | 115,134 | | | 17,725 | | | 54,093 | | | | | 186,952 | | | Prior periods | (625) | | | (1,162) | | | 97 | | | | | (1,690) | | | Payments and customer credits issued | (111,424) | | | (17,768) | | | (36,953) | | | | | (166,145) | | Balance at March 31, 2024 | $ | 28,306 | | | $ | 18,516 | | | $ | 57,135 | | | | | $ | 103,957 | |
|
| Schedule of Other Assets and Other Liabilities |
Contract assets and liabilities were as follows (in thousands): | | | | | | | | | | | | | March 31, 2024 | | December 31, 2023 | | | | | | | | | | | | | Contract assets (1) | $ | 1,343 | | | $ | 1,321 | | | | | | | Contract liabilities: | | | | Current portion (2) | $ | 4,054 | | | $ | 5,406 | | Long-term portion (3) | 4,922 | | | 5,524 | | | Total contract liabilities | $ | 8,976 | | | $ | 10,930 | |
____________________ (1) Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. (2) Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets. (3) Presented in other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets.
|